Beijing Tiantan Biological Products Co., Ltd. (600161.SS)
- Previous Close
28.16 - Open
28.06 - Bid 28.69 x --
- Ask 28.70 x --
- Day's Range
28.03 - 28.73 - 52 Week Range
23.00 - 32.73 - Volume
9,945,064 - Avg. Volume
10,722,896 - Market Cap (intraday)
47.276B - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
42.82 - EPS (TTM)
0.67 - Earnings Date Apr 26, 2024
- Forward Dividend & Yield 0.05 (0.18%)
- Ex-Dividend Date Jul 14, 2023
- 1y Target Est
31.48
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include human albumin; intravenous human immunoglobulin; tetanus human immunoglobulin; rabies patient immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; and human prothrombin complex blood products. The company was founded in 1919 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. is a subsidiary of China National Biotec Group Company Limited.
www.tiantanbio.comRelated News
Performance Overview: 600161.SS
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600161.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600161.SS
Valuation Measures
Market Cap
46.40B
Enterprise Value
41.89B
Trailing P/E
42.03
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.00
Price/Book (mrq)
4.72
Enterprise Value/Revenue
8.09
Enterprise Value/EBITDA
20.23
Financial Highlights
Profitability and Income Statement
Profit Margin
22.79%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
5.11B
Net Income Avi to Common (ttm)
1.16B
Diluted EPS (ttm)
0.67
Balance Sheet and Cash Flow
Total Cash (mrq)
4.55B
Total Debt/Equity (mrq)
0.33%
Levered Free Cash Flow (ttm)
--